Trial · NCT07883031
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fat Oxidation During Walking | Before and after each 6-week supplementation period. | Whole-body fat oxidation rate (g/min), calculated from oxygen uptake and carbon dioxide production measured by indirect calorimetry during standardized treadmill walking. |
| Primary | Walking Economy | Before and after each 6-week supplementation period. | Oxygen cost of walking, expressed in milliliters of oxygen per kilogram of body mass per meter walked. The value is calculated by dividing mass-specific oxygen uptake in mL/kg/min by walking speed in meters per minute. Lower values indicate better walking economy. |
| Primary | Fasting Triglycerides | Before and after each 6-week supplementation period. | Fasting triglyceride concentration (mg/dL), assessed using the Cholestech LDX system. |
| Primary | Psychomotor Vigilance Task Reaction Time | Before and after each 6-week supplementation period. | Reaction time, expressed in milliseconds, during the computerized Psychomotor Vigilance Task, which assesses sustained attention and vigilance. Shorter reaction times indicate faster responses. |
| Primary | Transcript Expression Fold Change | At the end of each 6-week supplementation period. | Expression of protein-coding and noncoding transcripts assessed using the Affymetrix Clariom D human microarray. Differences between yerba mate and placebo supplementation conditions are expressed as fold changes in transcript expression, with results reported individually for each transcript. |
| Primary | Eriksen Flanker Task Incongruent-Trial Reaction Time | Before and after each 6-week supplementation period. | Reaction time, expressed in milliseconds, during incongruent trials of the computerized Eriksen Flanker Task, which assesses inhibitory control. Shorter reaction times indicate faster performance. |
| Primary | Task-Switching Reaction Time | Before and after each 6-week supplementation period. | Reaction time, expressed in milliseconds, during the computerized task-switching task, which assesses cognitive flexibility. Shorter reaction times indicate faster performance. |
| Secondary | Fasting Blood Glucose | Before and after each 6-week supplementation period. | Fasting blood glucose concentration (mg/dL), measured using the Cholestech LDX system. |
| Secondary | Blood Pressure | Before and after each 6-week supplementation period. | Resting diastolic blood pressure (mmHg), measured using an automated upper-arm monitor after 5 minutes of seated rest. |
| Secondary | Interleukin-6 Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma interleukin-6 abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
| Secondary | Relative Abundance of Gut Bacterial Taxa | At the end of a 6-week supplementation period. | Relative abundance of bacterial taxa in stool samples assessed by sequencing the V3-V4 region of the bacterial 16S ribosomal RNA gene. Results are expressed as percentages of bacterial sequencing reads assigned to each taxon, ranging from 0% to 100%. Higher percentages indicate greater relative representation of the taxon in the sample. Taxa are reported individually and compared between yerba mate and placebo supplementation conditions. |
| Secondary | Tumor Necrosis Factor Alpha Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma tumor necrosis factor alpha abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
| Secondary | Interleukin-1 Beta Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma interleukin-1 beta abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
| Secondary | Interleukin-10 Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma interleukin-10 abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
| Secondary | Interferon Gamma Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma interferon gamma abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
| Secondary | Monocyte Chemoattractant Protein-1 Relative Abundance Fold Change | After each 6-week supplementation period. | Relative plasma monocyte chemoattractant protein-1, also known as C-C motif chemokine ligand 2, abundance assessed using a cytokine antibody array. Results are expressed as the dimensionless ratio of normalized signal intensity after yerba mate to that after placebo. A ratio of 1 indicates equal abundance between conditions; values above 1 indicate higher abundance after yerba mate, and values below 1 indicate lower abundance compared with placebo. |
| Secondary | Cognitive Failures Questionnaire Total Score | After each 6-week supplementation period. | Perceived cognitive failures assessed using the 25-item Cognitive Failures Questionnaire. Each item is scored from 0 to 4, yielding a total score from 0 to 100. Higher scores indicate more frequent cognitive failures and a worse outcome. |
| Secondary | World Health Organization-Five Well-Being Index Score | After each 6-week supplementation period. | Psychological well-being assessed using the World Health Organization-Five Well-Being Index. Five items are scored from 0 to 5. The summed score is multiplied by four to obtain a final score from 0 to 100. Higher scores indicate better psychological well-being. |
| Secondary | 15-Item Geriatric Depression Scale Total Score | After each 6-week supplementation period. | Depressive symptoms assessed using the 15-item Geriatric Depression Scale. The total score ranges from 0 to 15. Higher scores indicate more depressive symptoms and a worse outcome. |
| Secondary | Generalized Anxiety Disorder 7-Item Scale Total Score | After each 6-week supplementation period. | Anxiety symptoms assessed using the Generalized Anxiety Disorder 7-Item Scale. Each item is scored from 0 to 3, yielding a total score from 0 to 21. Higher scores indicate greater anxiety symptom severity and a worse outcome. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07883031/registered